166 related articles for article (PubMed ID: 15670251)
1. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.
Iloeje UH; Yuan Y; L'italien G; Mauskopf J; Holmberg SD; Moorman AC; Wood KC; Moore RD
HIV Med; 2005 Jan; 6(1):37-44. PubMed ID: 15670251
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
4. Protease inhibitors and cardiovascular disease: analysis of the Los Angeles County adult spectrum of disease cohort.
Vaughn G; Detels R
AIDS Care; 2007 Apr; 19(4):492-9. PubMed ID: 17453589
[TBL] [Abstract][Full Text] [Related]
5. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
6. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of abdominal wall hernia associated with combination anti-retroviral therapy in HIV-infected patients-results from a Swedish cohort-study.
Sundström A; Mortimer O; Akerlund B; Karlsson A; Flamholc L; Håkangård C; Granholm H; Persson I; Morfeldt L
Pharmacoepidemiol Drug Saf; 2010 May; 19(5):465-73. PubMed ID: 20186997
[TBL] [Abstract][Full Text] [Related]
9. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
11. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
[TBL] [Abstract][Full Text] [Related]
12. Gestational diabetes mellitus in a cohort of HIV-1 infected women.
González-Tomé MI; Ramos Amador JT; Guillen S; Solís I; Fernández-Ibieta M; Muñoz E; Almeda J; Rojano X; Rojo P; Nieto O;
HIV Med; 2008 Nov; 9(10):868-74. PubMed ID: 18983478
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.
Colafigli M; Di Giambenedetto S; Bracciale L; Tamburrini E; Cauda R; De Luca A
HIV Med; 2008 Mar; 9(3):172-9. PubMed ID: 18217998
[TBL] [Abstract][Full Text] [Related]
14. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study.
Ledergerber B; Furrer H; Rickenbach M; Lehmann R; Elzi L; Hirschel B; Cavassini M; Bernasconi E; Schmid P; Egger M; Weber R;
Clin Infect Dis; 2007 Jul; 45(1):111-9. PubMed ID: 17554711
[TBL] [Abstract][Full Text] [Related]
16. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study.
Tien PC; Schneider MF; Cole SR; Levine AM; Cohen M; DeHovitz J; Young M; Justman JE
AIDS; 2007 Aug; 21(13):1739-45. PubMed ID: 17690572
[TBL] [Abstract][Full Text] [Related]
18. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
[TBL] [Abstract][Full Text] [Related]
19. The impact of Type 2 diabetes and microalbuminuria on future cardiovascular events in patients with clinically manifest vascular disease from the Second Manifestations of ARTerial disease (SMART) study.
Soedamah-Muthu SS; Visseren FL; Algra A; van der Graaf Y;
Diabet Med; 2008 Jan; 25(1):51-7. PubMed ID: 18199132
[TBL] [Abstract][Full Text] [Related]
20. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection.
David MH; Hornung R; Fichtenbaum CJ
Clin Infect Dis; 2002 Jan; 34(1):98-102. PubMed ID: 11731952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
